ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 136
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
E
Asian physicians’ knowledge, attitudes and practices
towards herpes zoster (HZ) and HZ vaccination
Dr Jing Chen1, Jennifer Si2, Regina Gowindah2, Vince Grillo2, Dr Raunak Parikh3, Sumitra
Shantakumar4, Felix Chan5, Macy Chan6, Won Suk Choi7, Erick Huang8, Kuo-Chin Huang9, Li-Min
Huang10, Hyungwoo Kim11, Choon Kit Leong12, Hoe-Nam Leong13, Yubin Seo14, Charles Williams15,
Andrew TY Wong16
1
F
G
H
I
J
K
Epidemiology and Health Outcomes, GSK, 2Cerner Enviza, Singapore, 3Medical Affairs, GSK, Wavre,
Value Evidence and Outcomes, GSK, 5Division of Geriatric Medicine, University Department of
Medicine, University of Hong Kong, 6Medical Affairs, GSK, 7Department of Internal Medicine, Korea
University College of Medicine, Korea University Ansan Hospital, 8Medical Affairs, GSK, 9Department
of Family Medicine, National Taiwan University Hospital Hsin-Chu Branch, 10Department of Paediatrics,
National Taiwan University Hospital, 11Medical Affairs, GSK, Seoul, 12Mission Medical Clinic, Singapore,
13
Rophi Clinic, Mount Elizabeth Novena Specialist Centre, 14Department of Internal Medicine, Kangnam
Sacred Heart Hospital, Hallym University, 15Medical Affairs, GSK, 16Infectious Diseases, Central
Medical Practice
4
Aim and goals
To identify factors influencing herpes zoster (HZ) vaccination perceptions in selected Asia-Pacific
locales and to elicit physicians’ knowledge, attitudes and practices towards HZ disease and
vaccination.
Methods
A cross-sectional study across Hong Kong (HK), Singapore (SG), South Korea (SK) and Taiwan
(TW) was conducted in January–September 2022. Following concept elicitation interviews with 24
physicians, a 30-minute online survey was conducted with the same target population (infectious
diseases specialists [n = 15], geriatricians [n = 5], dermatologists [n = 20] and general practitioners/
family medicine [n = 180]; total n = 220). Descriptive analyses were used to summarise study
population responses and findings were presented as counts and percentages, based on categorical
variables.
Results
Most physicians knew about the risk factors for HZ (>80%). Top factors driving vaccine
recommendations for patients ≥50 years of age (YOA) included disease prevalence, impact of disease
on other health conditions, government recommendations/national vaccination lists and patients’
underlying diseases. Physicians agreed that HZ impacts quality of life. Nearly 90% expressed that HZ
vaccines were important to recommend to patients ≥50 YOA. However, HZ vaccination conversations
were initiated with
60%) were the most
reported barriers to initiating HZ vaccination conversations. Vaccine affordability was less of a concern
and reported by approximately one-third of physicians.
Conclusion
Efforts are needed to enhance translation of physicians’ understanding of HZ burden and vaccination
benefits into clinical practice. This includes removing barriers to initiating HZ vaccination conversations
and shared decision making with patients, including those with underlying diseases.
134